Chemomab Therapeutics Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Chemomab Therapeutics Ltd. (CMMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-23
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|
| 2025-12-31 | 0.00% 20-F · filed 2026-03-23 | ||
| 2024-12-31 | 0.00% 20-F · filed 2025-04-04 | ||
| 2023-12-31 | 0.00% 20-F · filed 2024-03-28 | ||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-20 | ||
| 2021-12-31 | 0.00% 10-K · filed 2022-03-30 | ||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-13 | ||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-09 |